| Literature DB >> 32298354 |
Jong Wook Choi1, Joon-Sung Park2, Chang Hwa Lee2.
Abstract
BACKGROUND: A high salt diet is associated with the development of hypertension, one of the most important cardiovascular risk factors. A reduction in sodium intake seems to have an effect on increasing serum triglycerides (TGs). Elevated TGs are independently linked to cardiovascular risk. However, there is limited evidence of a possible interactive effect of sodium intake and serum TGs on high blood pressure (BP).Entities:
Year: 2020 PMID: 32298354 PMCID: PMC7162459 DOI: 10.1371/journal.pone.0231707
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
General characteristics grouped according to e24UNaEKawasaki**.
| Quintile 1 | Quintile 2 | Quintile 3 | Quintile 4 | Quintile 5 | ||
|---|---|---|---|---|---|---|
| e24UNaEKawasaki in male (g/day) | ≥ 0.5, ≤ 3.2 | > 3.2, ≤ 3.9 | > 3.9, ≤ 4.6 | > 4.6, ≤ 5.4 | > 5.4, ≤ 17.4 | |
| e24UNaEKawasaki in female (g/day) | ≥ 0.6, ≤ 2.8 | > 2.8, ≤ 3.5 | > 3.5, ≤ 4.1 | > 4.1, ≤ 4.9 | > 4.9, ≤ 12.7 | |
| Variables | (n = 4093) | (n = 4091) | (n = 4095) | (n = 4095) | (n = 4088) | P |
| Age (year) | 39.2 ± 0.3 | 41,4 ± 0.3 | 43.5 ± 0.3 | 45.0 ± 0.3 | 46.1 ± 0.3 | <0.0001 |
| Sex (% male) | 1873 (46) | 1871 (46) | 1874 (46) | 1872 (46) | 1871 (46) | 0.9365 |
| Current smoker (%) | 1235 (30) | 1152 (28) | 1063 (26) | 1039 (25) | 1073 (26) | 0.0015 |
| Systolic blood pressure (mmHg) | 113.2 ± 0.2 | 115.1 ± 0.2 | 117.1 ± 0.3 | 119.0 ± 0.3 | 122.2 ± 0.3 | <0.0001 |
| Diastolic blood pressure (mmHg) | 73.7 ± 0.2 | 74.4 ± 0.2 | 75.6 ± 0.2 | 76.3 ± 0.2 | 77.6 ± 0.2 | <0.0001 |
| Body mass index (kg/m2) | 22.6 ± 0.1 | 23.1 ± 0.1 | 23.5 ± 0.1 | 23.9 ± 0.1 | 24.4 ± 0.1 | <0.0001 |
| Waist circumference (cm) | 77.7 ± 0.2 | 79.1 ± 0.2 | 80.6 ± 0.2 | 81.9 ± 0.2 | 83.5 ± 0.2 | <0.0001 |
| White blood cell count (109/L) | 6.44 ± 0.03 | 6.26 ± 0.03 | 6.29 ± 0.03 | 6.24 ± 0.03 | 6.27 ± 0.03 | <0.0001 |
| Hemoglobin (g/dL) | 14.36 ± 0.03 | 14.24 ± 0.03 | 14.21 ± 0.03 | 14.21 ± 0.03 | 14.18 ± 0.03 | 0.0005 |
| Platelets (103/μL) | 263.2 ± 1.1 | 259.3 ± 1.1 | 258.6 ± 1.0 | 255.6 ± 1.1 | 256.6 ± 1.1 | <0.0001 |
| eGFR | 101.4 ± 0.3 | 101.5 ± 0.3 | 100.5 ± 0.3 | 100.1 ± 0.3 | 101.5 ± 0.3 | 0.0073 |
| Fasting glucose (mg/dL) | 96.3 ± 0.4 | 96.1 ± 0.3 | 97.3 ± 0.3 | 97.9 ± 0.3 | 98.9 ± 0.3 | <0.0001 |
| Hemoglobin A1c (%) | 5.66 ± 0.02 | 5.67 ± 0.02 | 5.72 ± 0.02 | 5.77 ± 0.02 | 5.68 ± 0.02 | <0.0001 |
| Aspartate aminotransferase (IU/L) | 21.9 ± 0.2 | 21.7 ± 0.2 | 22.2 ± 0.2 | 22.7 ± 0.2 | 23.2 ± 0.2 | <0.0001 |
| Alanine aminotransferase (IU/L) | 20.9 ± 0.3 | 20.6 ± 0.2 | 21.8 ± 0.3 | 22.8 ± 0.3 | 23.3 ± 0.3 | <0.0001 |
| Triglycerides (mg/dL) | 118.9 ± 1.6 | 124.7 ± 1.7 | 133.0 ± 1.8 | 140.1 ± 2.1 | 149.5 ± 2.1 | <0.0001 |
| HDL cholesterol (mg/dL) | 51.3 ± 0.2 | 50.4 ± 0.2 | 49.7 ± 0.2 | 49.1 ± 0.2 | 48.8 ± 0.2 | <0.0001 |
| LDL cholesterol (mg/dL) | 110.5 ± 0.7 | 110.9 ± 0.8 | 120.0 ± 0.8 | 111.8 ± 0.8 | 112.1 ± 0.8 | 0.1047 |
| UACR (mg/g Cr) | 13.0 ± 1.9 | 11.4 ± 1.0 | 17.5 ± 3.2 | 19.9 ± 3.8 | 27.3 ± 4.6 | <0.0001 |
| Dietary intake | ||||||
| Total calories (Kcal/day) | 2046 ± 17 | 2082 ± 17 | 2095 ± 15 | 2103 ± 18 | 2091 ± 17 | 0.0129 |
| Protein intake (g/day) | 71.8 ± 0.7 | 74.2 ± 0.8 | 75.3 ± 0.8 | 75.1 ± 0.9 | 74.1 ± 0.8 | 0.0082 |
| Fat intake (g/day) | 47.4 ± 0.6 | 46.9 ± 0.6 | 46.1 ± 0.6 | 44.8 ± 0.7 | 42.6 ± 0.6 | <0.0001 |
| Carbohydrate intake (g/day) | 310.8 ± 2.2 | 318.3 ± 2.2 | 323.5 ± 2.1 | 329.5 ± 2.3 | 331.6 ± 2.4 | <0.0001 |
| Sodium intake (g/day) | 4.19 ± 0.05 | 4.48 ± 0.05 | 4.61 ± 0.05 | 4.86 ± 0.07 | 4.91 ± 0.06 | <0.0001 |
| Potassium intake (g/day) | 2.95 ± 0.03 | 3.04 ± 0.03 | 3.13 ± 0.03 | 3.16 ± 0.03 | 3.12 ± 0.03 | <0.0001 |
| Alcohol intake (g/day) | 2.2 ± 0.1 | 2.3 ± 0.1 | 2.3 ± 0.1 | 2.4 ± 0.1 | 2.6 ± 0.1 | <0.0001 |
| Morning fasting urine | ||||||
| Urine sodium (mmol/L) | 80.4 ± 05 | 112.7 ± 0.6 | 128.9 ± 0.7 | 144.6 ± 0.8 | 162.4 ± 1.0 | <0.0001 |
| Urine creatinine (mmol/L) | 22.3 ± 0.2 | 16.4 ± 0.1 | 13.4 ± 0.1 | 11.0 ± 0.1 | 7.9 ± 0.1 | <0.0001 |
| Urine Na/Cr ratio (mmol/mmol) | 3.93 ± 0.02 | 7.25 ± 0.03 | 10.23 ± 0.04 | 14.11 ± 0.06 | 23.37 ± 0.14 | <0.0001 |
| Estimated 24-h urine sodium excretion (e24UNaE) | ||||||
| e24UNaEKawasaki | 2.458 ± 0.007 | 3.382 ± 0.004 | 4.006 ± 0.005 | 4.710 ± 0.006 | 6.057 ± 0.014 | <0.0001 |
| e24UNaETakada | 2.129 ± 0.005 | 2.751 ± 0.003 | 3.152 ± 0.003 | 3.589 ± 0.003 | 4.370 ± 0.008 | <0.0001 |
| e24UNaEMage | 0.794 ± 0.005 | 1.458 ± 0.004 | 2.040 ± 0.006 | 2.819 ± 0.010 | 4.754 ± 0.029 | <0.0001 |
The results are expressed as the mean ± SD or frequencies (and proportions).
eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; Na, sodium; Cr, creatinine; UACR, urine albumin/Cr ratio.
*Estimated using the Chronic Kidney Disease Epidemiology Collaboration equation.
** e24UNaE calculated using the Kawasaki method.
*** e24UNaE calculated using the Takada method.
**** e24UNaE calculated using the Mage method.
Fig 1Relationship of e24UNaEKawasaki# with difference in (A) systolic blood pressure, (B) diastolic blood pressure, and (C) serum triglycerides compared with the chosen reference e24UNaEKawasaki of 3.9. The solid line represents the difference in systolic blood pressure, diastolic blood pressure, and triglycerides, and the dashed lines represent 95% confidential intervals. Histogram illustrates the distribution of e24UNaEKawasaki among participants. *Calculated by linear regression model of adjusted restricted cubic spline analysis using age, sex, and smoking history as covariates. #Estimated 24-h urinary sodium excretion calculated using the Kawasaki method.
Fig 2Nonlinear relationship between e24UNaEKawasaki and the odds ratio of hypertension# with the chosen reference e24UNaEKawasaki of 3.9.
The solid line represents the odds ratio of hypertension, and the dashed lines represent 95% confidential intervals. Histogram illustrates the distribution of e24UNaEKawasaki among participants. *Calculated by linear regression model of adjusted restricted cubic spline analysis using age, sex, and smoking history as covariates and body mass index, waist circumference, white blood cell count, hemoglobin, fasting plasma glucose, hemoglobin A1c, aspartate aminotransferase, alanine aminotransferase, UACR, and daily alcohol intake as predictors. #Defined as the use of antihypertensive therapy, systolic BP above 140 mmHg or a diastolic BP above 90 mmHg. UACR, urine albumin/Cr ratio.
Multivariable logistic regression for hypertension*.
| Crude | Model I | Model II | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Variable | OR | 95% | P | OR | 95% | P | OR | 95% | P |
| Age (year) | 1.063 | 1.060–1.066 | <0.0001 | ||||||
| Female (vs. male) | 0.624 | 0.578–0.672 | <0.0001 | ||||||
| Smoker (vs. nonsmoker) | 1.204 | 1.106–1.310 | <0.0001 | ||||||
| Body mass index (kg/m2) | 1.180 | 1.165–1.197 | <0.0001 | ||||||
| Waist circumference (cm) | 1.063 | 1.059–1.068 | <0.0001 | ||||||
| White blood cell count (109/L) | 1.106 | 1.078–1.134 | <0.0001 | ||||||
| Hemoglobin (g/dL) | 1.348 | 1.290–1.409 | <0.0001 | ||||||
| Platelets (103/μL) | 0.999 | 0.998–0.999 | <0.0001 | ||||||
| eGFR (mL·min-1·1.73 m-2) | 0.954 | 0.951–0.957 | <0.0001 | ||||||
| Fasting plasma glucose (mg/dL) | 1.058 | 1.053–1.063 | <0.0001 | ||||||
| Hemoglobin A1c (%) | 3.347 | 2.794–4.009 | <0.0001 | ||||||
| Aspartate aminotransferase (IU/L) | 1.030 | 1.024–1.036 | <0.0001 | ||||||
| Alanine aminotransferase (IU/L) | 1.015 | 1.012–1.018 | <0.0001 | ||||||
| Triglycerides (mg/dL) | 1.003 | 1.003–1.004 | <0.0001 | 1.001 | 1.001–1.002 | <0.0001 | |||
| HDL cholesterol (mg/dL) | 0.978 | 0.974–0.982 | <0.0001 | 0.998 | 0.990–1.007 | 0.7126 | |||
| LDL cholesterol (mg/dL) | 1.008 | 1.006–1.010 | <0.0001 | 1.002 | 0.996–1.008 | 0.4896 | |||
| UACR (mg/g Cr) | 1.079 | 1.065–1.093 | <0.0001 | ||||||
| Dietary intake | |||||||||
| Total calories (Kcal/day) | 1.001 | 1.001–1.001 | <0.0001 | 1.000 | 0.999–1.001 | 0.3397 | |||
| Protein intake (g/day) | 0.998 | 0.997–0.999 | <0.0001 | 1.000 | 0.999–1.001 | 0.4649 | |||
| Fat intake (g/day) | 0.992 | 0.990–0.994 | <0.0001 | 1.000 | 0.998–1.001 | 0.5359 | |||
| Carbohydrate intake (g/day) | 1.000 | 0.999–1.001 | 0.3327 | ||||||
| Sodium intake (g/day) | 1.001 | 0.990–1.013 | 0.8377 | ||||||
| Potassium intake (g/day) | 0.973 | 0.948–0.999 | <0.0001 | 0.983 | 0.954–1.012 | 0.2398 | |||
| Alcohol intake (g/day) | 1.096 | 1.083–1.108 | <0.0001 | 1.091 | 1.076–1.107 | <0.0001 | |||
| Estimated 24-h urine sodium excretion | |||||||||
| e24UNaEKawasaki (g/day) | 1.241 | 1.203–1.281 | <0.0001 | 1.107 | 1.024–1.197 | 0.0107 | 1.115 | 1.027–1.210 | 0.0092 |
| e24UNaETanaka (g/day) | 1.454 | 1.382–1.530 | <0.0001 | 1.142 | 1.008–1.295 | 0.0376 | 1.157 | 1.015–1.320 | 0.0294 |
| e24UNaEMage (g/day) | 1.148 | 1.116–1.181 | <0.0001 | 1.095 | 1.028–1.166 | 0.0050 | 1.104 | 1.033–1.181 | 0.0039 |
* Defined as either the use of antihypertensive therapy and/or systolic BP above 140 mm Hg or a diastolic BP above 90 mm Hg.
Model I, performed using age, sex, and smoking as covariates and body mass index, waist circumference, white blood cell count, hemoglobin, eGFR, fasting plasma glucose, hemoglobin A1c, aspartate aminotransferase, alanine aminotransferase, UACR, and daily alcohol intake as predictors.
Model II, performed using age, sex, and smoking as covariates and body mass index, waist circumference, white blood cell count, hemoglobin, eGFR, fasting plasma glucose, hemoglobin A1c, aspartate aminotransferase, alanine aminotransferase, triglycerides, UACR, and daily alcohol intake as predictors.
OR, odds ratio; CI, confidence interval.
Fig 3Prevalence of hypertension# according to e24UNaEKawasaki and serum triglyceride quintile.
*Estimated using the Cochran-Armitage test for trend.
Interactive effect analysis of high sodium intake and increased triglyceride level on hypertension.
| Categories | Unadjusted | Adjusted | |||||
|---|---|---|---|---|---|---|---|
| Triglyceride quintile | e24UNaEKawasaki quintile | OR | 95% | P | OR | 95% | P |
| 1–3 | 1–2 | 1 (reference) | 1 (reference) | ||||
| 1–3 | 3–5 | 1.590 | 1.413–1.790 | <0.0001 | 1.128 | 0.867–1.467 | 0.3685 |
| 4–5 | 1–2 | 2.488 | 2.183–2.835 | <0.0001 | 1.314 | 0.972–1.777 | 0.0762 |
| 4–5 | 3–5 | 3.331 | 2.976–3.727 | <0.0001 | 1.526 | 1.091–2.134 | 0.0137 |
*Adjusted for age, sex, smoking history, body mass index, waist circumference, white blood cell count, hemoglobin, eGFR, fasting plasma glucose, hemoglobin A1c, aspartate aminotransferase, alanine aminotransferase, UACR, and daily alcohol intake.
Index of additive biological interactive effect of high sodium intake and increased triglyceride level on hypertension.
| Unadjusted | Adjusted | |||
|---|---|---|---|---|
| Measure | Estimate | 95% | Estimate | 95% |
| RERI | 0.051 | 0.045–0.056 | 0.008 | 0.002–0.014 |
| AP | 0.038 | 0.017–0.058 | 0.015 | 0.008–0.022 |
| SI | 1.168 | 1.052–1.284 | 1.119 | 1.101–1.137 |
*Adjusted for age, sex, smoking history, body mass index, waist circumference, white blood cell count, hemoglobin, fasting plasma glucose, hemoglobin A1c, aspartate aminotransferase, alanine aminotransferase, UACR, and daily alcohol intake.
If there was no biological interaction, the 95% CI of RERI and AP included 0, and the 95% CI of SI contained 1.
RERI, the relative excess risk because of the interaction; AP, the attributable proportion of the interaction; SI, the additive interaction index of synergy.